These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10970102)

  • 1. The peptide-binding motif of HLA-B*3505.
    Kenneally A; Liang B; Barber LD
    Immunogenetics; 2000 Aug; 51(10):866-8. PubMed ID: 10970102
    [No Abstract]   [Full Text] [Related]  

  • 2. An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide.
    Dong T; Boyd D; Rosenberg W; Alp N; Takiguchi M; McMichael A; Rowland-Jones S
    Eur J Immunol; 1996 Feb; 26(2):335-9. PubMed ID: 8617300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the obstacle of incompatibility at residue 156 within HLA-B*35 subtypes.
    Manandhar T; Kunze-Schumacher H; Huyton T; Celik AA; Blasczyk R; Bade-Doeding C
    Immunogenetics; 2016 Apr; 68(4):247-60. PubMed ID: 26758079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interaction.
    Khanna R; Silins SL; Weng Z; Gatchell D; Burrows SR; Cooper L
    Eur J Immunol; 1999 May; 29(5):1587-97. PubMed ID: 10359113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational restraints and flexibility of 14-meric peptides in complex with HLA-B*3501.
    Probst-Kepper M; Hecht HJ; Herrmann H; Janke V; Ocklenburg F; Klempnauer J; van den Eynde BJ; Weiss S
    J Immunol; 2004 Nov; 173(9):5610-6. PubMed ID: 15494511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults.
    Udhayakumar V; Ongecha JM; Shi YP; Aidoo M; Orago AS; Oloo AJ; Hawley WA; Nahlen BL; Hoffman SL; Weiss WR; Lal AA
    Eur J Immunol; 1997 Aug; 27(8):1952-7. PubMed ID: 9295031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of specific amino acid substitutions in HLA-B35-restricted human immunodeficiency virus type 1 cytotoxic T lymphocyte epitopes.
    Kawana A; Tomiyama H; Takiguchi M; Shioda T; Nakamura T; Iwamoto A
    AIDS Res Hum Retroviruses; 1999 Aug; 15(12):1099-107. PubMed ID: 10461830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crucial role of N-terminal residue of binding peptides in recognition of the monoclonal antibody specific for the peptide-HLA-B5, -B35 complex.
    Sakaguchi T; Takamiya Y; Edidin M; Nokihara K; Miwa K; Schönbach C; Takiguchi M
    Immunogenetics; 1998; 47(2):149-58. PubMed ID: 9396861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microheterogeneity in HLA-B35 alleles influences peptide-dependent allorecognition by cytotoxic T cells but not binding of a peptide-restricted monoclonal antibody.
    Steinle A; Reinhardt C; Nössner E; Uchanska-Ziegler B; Ziegler A; Schendel DJ
    Hum Immunol; 1993 Dec; 38(4):261-9. PubMed ID: 8138421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fine tuning of peptide binding to HLA-B*3501 molecules by nonanchor residues.
    Schönbach C; Ibe M; Shiga H; Takamiya Y; Miwa K; Nokihara K; Takiguchi M
    J Immunol; 1995 Jun; 154(11):5951-8. PubMed ID: 7751638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes.
    Morel S; Ooms A; Van Pel A; Wölfel T; Brichard VG; van der Bruggen P; Van den Eynde BJ; Degiovanni G
    Int J Cancer; 1999 Dec; 83(6):755-9. PubMed ID: 10597191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of human minor histocompatibility antigens: T cell recognition of human minor histocompatibility peptides presented by HLA-B35 subtype molecules.
    Beck Y; Satz L; Takamiya Y; Nakayama S; Ling L; Ishikawa Y; Nagao T; Uchida H; Tokunaga K; Müller C
    J Exp Med; 1995 Jun; 181(6):2037-48. PubMed ID: 7759996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large scale mass spectrometric profiling of peptides eluted from HLA molecules reveals N-terminal-extended peptide motifs.
    Escobar H; Crockett DK; Reyes-Vargas E; Baena A; Rockwood AL; Jensen PE; Delgado JC
    J Immunol; 2008 Oct; 181(7):4874-82. PubMed ID: 18802091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS.
    Tomiyama H; Miwa K; Shiga H; Moore YI; Oka S; Iwamoto A; Kaneko Y; Takiguchi M
    J Immunol; 1997 May; 158(10):5026-34. PubMed ID: 9144523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules.
    Luiten RM; Demotte N; Tine J; van der Bruggen P
    Tissue Antigens; 2000 Jul; 56(1):77-81. PubMed ID: 10958359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A human CTL recognizes a caspase-8-derived peptide on autologous HLA-B*3503 molecules and two unrelated peptides on allogeneic HLA-B*3501 molecules.
    Mandruzzato S; Stroobant V; Demotte N; van der Bruggen P
    J Immunol; 2000 Apr; 164(8):4130-4. PubMed ID: 10754307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
    Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
    J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic peptides based on Chlamydia trachomatis antigens identify cytotoxic T lymphocyte responses in subjects from a trachoma-endemic population.
    Holland MJ; Conway DJ; Blanchard TJ; Mahdi OM; Bailey RL; Whittle HC; Mabey DC
    Clin Exp Immunol; 1997 Jan; 107(1):44-9. PubMed ID: 9010255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition.
    Burrows JM; Bell MJ; Brennan R; Miles JJ; Khanna R; Burrows SR
    Mol Immunol; 2008 Mar; 45(6):1818-24. PubMed ID: 17981331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refined peptide HLA-B*3501 binding motif reveals differences in 9-mer to 11-mer peptide binding.
    Schönbach C; Miwa K; Ibe M; Shiga H; Nokihara K; Takiguchi M
    Immunogenetics; 1996; 45(2):121-9. PubMed ID: 8952961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.